SynthesisRheumatology international2010
A systematic review and meta-analysis of the efficacy and safety of adalimumab for treating rheumatoid arthritis.
Synthesis in Rheumatology international, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03273192 (A Randomised, Double-blind, Single-dose, Parallel-group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of CinnoRA®), which is not on this map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Double-blind, Single-dose, Parallel-group Study in Healthy Subjects to Demonstrate Pharmacokinetic Equivalence of CinnoRA® (Produced by CinnaGen CO.) and Humira® (the Reference Drug, Produced by AbbVie Inc.)
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Efficacy and Safety of ABBV-154 for the Treatment of Active Rheumatoid Arthritis: A Phase 2b, Randomized, Placebo-Controlled Trial.Arthritis & rheumatology (Hoboken, N.J.) · 2025Trial
- B Cells or T Cells in the Development and Sustenance of Rheumatoid Arthritis: Who is the Potential Contributor?Mediterranean journal of rheumatology · 2026Review
- Role of macrophages and dendritic cells in autoimmune diseases: a specific focus on tumor necrosis factor targeting therapies against rheumatoid arthritis.Molecular biology reports · 2026Review
- Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort.Medicina (Kaunas, Lithuania) · 2022Observational
- Current and novel therapeutic targets in the treatment of rheumatoid arthritis.Inflammopharmacology · 2020Review
- Structural optimization of a TNFR1-selective antagonistic TNFα mutant to create new-modality TNF-regulating biologics.The Journal of biological chemistry · 2020Article
- Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab.Drug safety · 2018Article
- Functions of interleukin-34 and its emerging association with rheumatoid arthritis.Immunology · 2016Review
- A multi-targeted approach to suppress tumor-promoting inflammation.Seminars in cancer biology · 2015Review
- Inflammation and cancer: advances and new agents.Nature reviews. Clinical oncology · 2015Review
- Cytokine-modulating strategies and newer cytokine targets for arthritis therapy.International journal of molecular sciences · 2014Review
- Hip score and disease activity correlation in patients with rheumatoid arthritis after total hip arthroplasty.International orthopaedics · 2013Observational
- TNF inhibitor therapy for rheumatoid arthritis.Biomedical reports · 2013Review
- Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure.Clinical rheumatology · 2013Article
- Repeat etanercept administration restores clinical response of patients with rheumatoid arthritis.Rheumatology international · 2012Article
- Adalimumab (Humira™): a promising monoclonal anti-tumor necrosis factor alpha in ophthalmology.International ophthalmology · 2011Review
- Adalimumab (humira™) in ophthalmology: a review of the literature.Middle East African journal of ophthalmology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Adalimumab (ADA) is a monoclonal antibody. Published studies indicate that its use in patients with rheumatoid arthritis can be efficient in providing long-term benefits. The aim of this study is to evaluate the efficacy and safety of ADA for treating rheumatoid arthritis. A systematic review was performed to search for randomized clinical trials that compare subcutaneous doses of ADA 20 mg weekly or 40 mg every other week with placebo, with or without concomitant methotrexate. Only studies of moderate or high quality were included. A meta-analysis was conducted to assess the efficacy (based in changes of American College of Rheumatology ACR criteria) and the safety (based in serious adverse events, serious infections, malignancy and deaths) of ADA use. Withdrawals due to adverse events or lack of efficacy were also evaluated. Eight studies met the inclusion criteria, comprising 2,692 patients. In the efficacy meta-analysis, a greater number of ADA-treated patients relative to those in placebo group achieved ACR20, ACR50 and ACR70 values from 6 months to 2 years of treatment. For safety results, there were no statistically significant differences between the groups. Withdrawals due to adverse events were higher in ADA group relative to the placebo group, and withdrawals due to the lack of efficacy were higher in placebo group relative to the ADA-treated group. This meta-analysis shows a higher efficacy of ADA relative to placebo, but clinicians should be careful regarding adverse events in ADA-treated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.